Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders

Biotechnology Journal

Volumn 3, Issue 12, 2008, Pages 1555-1563

  Terzi, Dimitra ^a   Zachariou, Venetia ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Alzheimer's disease; Parkinson's disease; Spinal cord trauma; Virus mediated gene transfer

Indexed keywords

AAV VECTORS; ADENO-ASSOCIATED VIRUS; ALZHEIMER'S DISEASE; ANIMAL MODELS; CLINICAL STUDIES; GENE DELIVERIES; GENE THERAPIES; PARKINSON'S DISEASE; SPINAL CORD TRAUMA;

DISEASES; DOSIMETRY; VIRUSES;

GENE TRANSFER;

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLERA TOXIN B SUBUNIT; COMPLEMENTARY DNA; ENDOTHELIN CONVERTING ENZYME; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PARVOVIRUS VECTOR; PROTEIN; PROTEIN L1; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; CLINICAL TRIAL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; LOW DRUG DOSE; MENINGOENCEPHALITIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; ADENOVIRUS; ANIMAL; DEGENERATIVE DISEASE; GENE VECTOR; GENETIC TRANSFECTION; GENETICS;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEURODEGENERATIVE DISEASES; SPINAL CORD INJURIES; TRANSFECTION;

EID: 59049096074     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200800284     Document Type: Review

References (82)

1. McCown, T. J., Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 2005, 5, 333-338.
2. Peel, A. L., Klein, R. L., Adeno-associated virus vectors: Activity and applications in the CNS. J. Neurosci. Methods 2000, 98, 95-104.
3. Ruitenberg, M. J., Eggers, R., Boer, G. J., Verhaagen, J., Adeno-associated viral vectors as agents for gene delivery: Application in disorders and trauma of the central nervous system. Methods 2002, 28, 182-194.
4. Balague, C., Kalla, M., Zhang, W. W., Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J. Virol. 1997, 71, 3299-3306.
5. Manning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A., Dwarki, V., Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 1998, 9, 477-485.
6. Bartlett, J. S., Samulski, R. J., McCown,T. J., Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 1998, 9, 1181-1186.
7. Chen, H., McCarty, D. M., Bruce, A. T., Suzuki, K., Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther. 1998, 5, 50-58.
8. Keir, S. D., Miller, J., Yu, G., Hamilton, R. et al., Efficient gene transfer into primary and immortalized human fetal glial cells using adeno-associated virus vectors: Establishment of a glial cell line with a functional CD4 receptor. J. Neurovirol. 1997, 3, 322-330.
9. Taymans, J. M., Vandenberghe, L. H., Haute, C. V., Thiry, I. et al., Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 2007, 18, 195-206.
10. Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I. et al., Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 2000, 97, 3428-3432.
11. Wang, C., Wang, C. M., Clark, K. R., Sferra,T. J., Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. 2003, 10, 1528-1534.
12. Ding W, Zhang L., YanZ and Engelhardt J. F., Intracellular trafficking of adeno associated viral vectors. Gene Ther. 2005, 12, 873-880.
13. McCown, T. J., Xiao, X., Li, J., Breese, G. R., Samulski, R. J., Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 1996, 713, 99-107.
14. Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., Hope, T. J., Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: Implications for gene therapy. Hum. Gene Ther. 1999, 10, 2295-2305.
15. Xu, R., Janson, C. G., Mastakov, M., Lawlor, P. et al., Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 2001, 8, 1323-1332.
16. Shevtsova, Z., Malik, J. M., Michel, U., Bahr, M., Kugler, S., Promoters and serotypes: Targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp. Physiol. 2005, 90, 53-59.
17. Klein, R. L., Lewis, M. H., Muzyczka, N., Meyer, E. M., Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 1999, 847, 314-320.
18. Klein, R. L., Meyer, E. M., Peel, A. L., Zolotukhin, S. et al., Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 1998, 150, 183-194.
19. Tenenbaum, L., Jurysta, F., Stathopoulos, A., Puschban, Z. et al., Tropism of AAV-2 vectors for neurons of the globus pallidus. Neuroreport 2000, 11, 2277-2283.
20. Klein, R. L., Hamby, M. E., Gong, Y., Hirko, A. C. et al., Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp. Neurol. 2002, 176, 66-74.
21. Peel, A. L., Zolotukhin, S., Schrimsher, G. W., Muzyczka, N., Reier, P. J., Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 1997, 4, 16-24.
22. Franich, N. R., Fitzsimons, H. L., Fong, D. M., Klugmann, M. et al., AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther. 2008, 16, 947-956.
23. Tenenbaum, L., Chtarto, A., Lehtonen, E., Velu, T. et al., Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. 2004, 6 Suppl 1, S212-222.
24. Ma, H. I., Lin, S. Z., Chiang, Y. H., Li, J. et al., Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 2002, 9, 2-11.
25. Yoshida, J., Mizuno, M., Nakahara, N., Colosi, P., Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma. Jpn. J. Cancer Res. 2002, 93, 223-228.
26. Mandel, R. J., Burger, C., Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Curr. Opin. Mol. Ther. 2004, 6, 482-490.
27. Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Macias, R. et al., Pathophysiologic basis of surgery for Parkinson's disease. Neurology 2000, 55, S7-12.
28. Wichmann, T., DeLong, M. R., Pathophysiology of Parkinson's disease: The MPTP primate model of the human disorder. Ann. N. Y. Acad. Sci. 2003, 991, 199-213.
29. Encarnacion, E. V., Hauser, R. A., Levodopa-induced dyskinesias in Parkinson's disease: Etiology, impact on quality of life, and treatments. Eur. Neurol. 2008, 60, 57-66.
30. Mochizuki, H., Mizuno, Y., Gene therapy for Parkinson's disease. J. Neural Transm. Suppl. 2003, 205-213.
31. Ozawa, K., Fan, D. S., Shen, Y., Muramatsu, S. et al., Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. J. Neural Transm. Suppl. 2000, 181-191.
32. Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L. et al., Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000, 23, S8-19.
33. Szczypka, M. S., Rainey, M. A., Kim, D. S., Alaynick, W. A. et al., Feeding behavior in dopamine-deficient mice. Proc. Natl. Acad. Sci. USA 1999, 96, 12138-12143.
34. Szczypka, M. S., Mandel, R. J., Donahue, B. A., Snyder, R. O. et al., Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron 1999, 22, 167-178.
35. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X. et al., Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 1994, 8, 148-154.
36. Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J., Bankiewicz, K. S., Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. 2001, 4, 324-330.
37. Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R. et al., Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 2006, 14, 564-570.
38. Sanftner, L. M., Sommer, J. M., Suzuki, B. M., Smith, P. H. et al., AAV2-mediated gene delivery to monkey putamen: Evaluation of an infusion device and delivery parameters. Exp. Neurol. 2005, 194, 476-483.
39. Forsayeth, J. R., Eberling, J. L., Sanftner, L. M., Zhen, Z. et al., A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys. Mol. Ther 2006, 14, 571-577.
40. Bankiewicz, K. S., Daadi, M., Pivirotto, P., Bringas, J. et al., Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp. Neurol. 2006, 197, 363-372.
41. Fan, D. S., Ogawa, M., Fujimoto, K. I., Ikeguchi, K. et al., Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 1998, 9, 2527-2535.
42. Shen, Y., Muramatsu, S. I., Ikeguchi, K., Fujimoto, K. I. et al., Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. 2000, 11, 1509-1519.
43. Muramatsu, S., Fujimoto, K., Ikeguchi, K., Shizuma, N. et al., Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 2002, 13, 345-354.
44. Mandel, R. J., Snyder, R. O., Leff, S. E., Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp. Neurol. 1999, 160, 205-214.
45. Mandel, R. J., Spratt, S. K., Snyder, R. O., Leff, S. E., Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA 1997, 94, 14083-14088.
46. Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K. et al., Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 2002, 9, 381-389.
47. Chen, Y. H., Harvey, B. K., Hoffman, A. F., Wang, Y. et al., MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J. 2008, 22, 261-275.
48. Tian, Y. Y., Tang, C. J., Wang, J. N., Feng, Y. et al., Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors. Neurosci. Lett. 2007, 421, 239-244.
49. Lee, B., Lee, H., Nam, Y. R., Oh, J. H. et al., Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther. 2005, 12, 1215-1222.
50. Emborg, M. E., Carbon, M., Holden, J. E., During, M. J. et al., Subthalamic glutamic acid decarboxylase gene therapy: Changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab. 2007, 27, 501-509.
51. Muchowski, P. J., Wacker, J. L., Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6, 11-22.
52. Zach, S., Bueler, H., Hengerer, B., Gillardon, F., Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture. Cell. Mol. Neurobiol. 2007, 27, 505-515.
53. St Martin, J. L., Klucken, J., Outeiro, T. F., Nguyen, P. et al., Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 2007, 100, 1449-1457.
54. Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y., Mochizuki, H., Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 2006, 341, 1088-1095.
55. Feigin, A., Kaplitt, M. G., Tang, C., Lin, T. et al., Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA 2007, 104, 19559-19564.
56. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L. et al., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 2007, 369, 2097-2105.
57. Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P. et al., Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70, 1980-1983.
58. Bartus, R. T., Dean, R. L. 3rd, Beer, B., Lippa, A. S., The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-414.
59. Masliah, E., Terry, R. D., DeTeresa, R. M., Hansen, L. A., Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 1989, 103, 234-239.
60. De Strooper, B., Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8, 141-146.
61. Zheng, H., Koo, E. H., The amyloid precursor protein: Beyond amyloid. Mol. Neurodegener. 2006, 1, 5.
62. Gnahn, H., Hefti, F., Heumann, R., Schwab, M. E., Thoenen, H., NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: Evidence for a physiological role of NGF in the brain? Brain Res. 1983, 285, 45-52.
63. Varon, S., Hagg, T., Fass, B., Vahlsing, L., Manthorpe, M., Neuronotrophic factors in cellular functional and cognitive repair of adult brain. Pharmacopsychiatry 1989, 22 Suppl 2, 120-124.
64. Tuszynski, M. H., Roberts, J., Senut, M. C., U, H. S., Gage, F. H., Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 1996, 3, 305-314.
65. Venero, J. L., Hefti, F., Knusel, B., Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: Comparison between intraparenchymal and intraventricular administration. Mol. Pharmacol. 1996, 49, 303-310.
66. Klein, R. L., Hirko, A. C., Meyers, C. A., Grimes, J. R. et al., NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res. 2000, 875, 144-151.
67. Isaacson, L. G., Billieu, S. C., Increased perivascular norepinephrine following intracerebroventricular infusion of NGF into adult rats. Exp. Neurol. 1996, 139, 54-60.
68. Williams, L. R., Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp. Neurol. 1991, 113, 31-37.
69. Tuszynski, M.H., Thal, L., Pay, M., Salmon, D. P. et al., A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11, 551-555.
70. Hara, H., Monsonego, A., Yuasa, K., Adachi, K. et al., Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis. 2004, 6, 483-488.
71. Mouri, A., Noda, Y., Hara, H., Mizoguchi, H. et al., Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 2007, 21, 2135-2148.
72. Zhang, J., Wu, X., Qin, C., Qi, J. et al., A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2003, 14, 365-379.
73. Gilman, S., Koller, M., Black, R. S., Jenkins, L. et al., Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64, 1553-1562.
74. Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B. et al., Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61, 46-54.
75. Fukuchi, K., Tahara, K., Kim, H. D., Maxwell, J. A. et al., Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 2006, 23, 502-511.
76. Levites, Y., Jansen, K., Smithson, L. A., Dakin, R. et al., Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. 2006, 26, 11923-11928.
77. Carty, N. C., Nash, K., Lee, D., Mercer, M. et al., Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol. Ther. 2008, 16, 1580-1586.
78. Eaton, M. J., Blits, B., Ruitenberg, M. J., Verhaagen, J., Oudega, M., Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther. 2002, 9, 1387-1395.
79. Blits, B., Oudega, M., Boer, G. J., Bartlett Bunge, M., Verhaagen, J., Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function. Neuroscience 2003, 118, 271-281.
80. Blits, B., Carlstedt, T. P., Ruitenberg, M. J., de Winter, F. et al., Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor. Exp. Neurol. 2004, 189, 303-316.
81. Ruitenberg, M. J., Blits, B., Dijkhuizen, P. A., te Beek, E. T. et al., Adeno-associated viral vector-mediated gene transfer of brain-derived neurotrophic factor reverses atrophy of rubrospinal neurons following both acute and chronic spinal cord injury. Neurobiol. Dis. 2004, 15, 394-406.
82. Chen, J., Wu, J., Apostolova, I., Skup, M. et al., Adeno-associated virus-mediated L1 expression promotes functional recovery after spinal cord injury. Brain 2007, 130, 954-969.